Related Experiment Video
Updated: Mar 21, 2026
04:53
Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
1.6K
Recognizing and managing insomnia in primary care and specialty settings
The Journal of Clinical Psychiatry
|May 4, 2016
Summary
Insomnia frequently accompanies medical and psychiatric conditions, negatively impacting patient well-being and increasing healthcare costs. This webcast details screening and evidence-based treatment strategies for insomnia in diverse patient populations.
Area of Science:
- Medical and Psychiatric Disorders
- Sleep Medicine
- Clinical Practice
Background:
- Insomnia is a prevalent issue in patients with medical and psychiatric conditions.
- It significantly impairs quality of life, daily functioning, and workplace productivity.
- Unmanaged insomnia contributes to increased healthcare expenditures.
Purpose of the Study:
- To provide guidance on screening for insomnia in patients with comorbid medical and mental illnesses.
- To outline the development of comprehensive, evidence-based treatment plans for insomnia.
- To review current evidence-based therapies, including behavioral interventions and pharmacotherapy.
Main Methods:
- The content is based on a review of evidence-based therapies for insomnia.
- The webcast focuses on practical screening and treatment planning strategies.
- Expert review of current literature and clinical guidelines informs the recommendations.
Main Results:
- Effective screening and treatment of insomnia can improve patient outcomes.
- A multimodal approach combining psychological and pharmacological interventions is often necessary.
- Early identification and management are key to mitigating negative consequences.
Conclusions:
- Healthcare providers should routinely screen for insomnia in patients with medical and psychiatric disorders.
- Comprehensive treatment plans tailored to individual patient needs are essential.
- Evidence-based therapies, including cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy, are effective.
Related Concept Videos
01:19Management of Insomnia
766
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
766
01:27Insomnia
571
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
571
01:13Insufficient Sleep and Sleep Deprivation
1.2K
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
1.2K
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
801
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
801
01:14CNS Depressants: Barbiturates and Benzodiazepines
1.6K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.6K
01:23Sedatives and Hypnotics: Overview
1.9K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
1.9K